# Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

> **NCT00168766** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 345 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Interferon-beta-1a (Avonex) plus methylprednisolone

## Key facts

- **NCT ID:** NCT00168766
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2013-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168766, "Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00168766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*